Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach

Area of Science:

• Metabolomics
• Liver Disease Research
• Biomarker Discovery

Background:

• Nonalcoholic fatty liver disease (NAFLD) encompasses stages from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH).
• Distinguishing between NAFL, early NASH, and advanced NASH is crucial for patient management but often relies on invasive biopsies.
• Identifying non-invasive biomarkers for disease severity is a significant unmet need.

Purpose of the Study:

• To identify distinct metabolite profiles and metabolic pathways differentiating NAFL, early NASH, and advanced NASH.
• To discover potential non-invasive biomarkers for assessing NAFLD histological severity.
• To investigate the role of specific metabolites, such as spermidine, in NAFLD progression.

Main Methods:

• Multiplatform metabolomics analysis of fasting serum samples from 57 patients with histologically-proven NAFLD.
• Utilized liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy.
• Applied multivariate statistical and pathway analysis to identify metabolite clusters and associations with disease severity.

Main Results:

• Metabolite profiling revealed distinct clusters for NAFL, early NASH, and advanced NASH.
• Spermidine levels were significantly lower (over 2-fold) in advanced NASH compared to NAFL and early NASH, indicating a potential protective effect.
• Metabolic pathway perturbations were identified between early and advanced NASH stages.

Conclusions:

• Multiplatform metabolomics effectively identified unique metabolite profiles and pathways distinguishing NAFL, early NASH, and advanced NASH.
• Spermidine emerged as a potential biomarker associated with less severe NAFLD histology, warranting further investigation for its protective role.
• These findings offer insights into NAFLD pathogenesis and potential non-invasive biomarkers for disease staging.